Who
Mark Andrew Wilson
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Septerna; Chief Legal Officer, Nektar Therapeutics.
In numbers
- Trades disclosed
- 45
- Buys
- 0
- Sells
- 26
- Bought
- $0
- Sold
- $674K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 18 May 2020
- Last trade
- 6 Feb 2026
- Last filed
- 10 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Feb 2026filed 10 Feb 2026 | SEPN Septernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —165,000 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | SEPN Septernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —165,000 at $0.00 | filing |
| 25 Nov 2025filed 25 Nov 2025 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $34K630 at $54.28 | filing |
| 21 Nov 2025filed 25 Nov 2025 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,400 at $0.00 | filing |
| 21 Nov 2025filed 25 Nov 2025 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,903 at $0.00 | filing |
| 19 Aug 2025filed 21 Aug 2025 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,666 at $0.00 | filing |
| 19 Aug 2025filed 21 Aug 2025 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $18K676 at $26.59 | filing |
| 19 May 2025filed 21 May 2025 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $6,6979,996 at $0.67 | filing |
| 19 Feb 2025filed 21 Feb 2025 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $11K11,040 at $1.01 | filing |
| 24 Dec 2024filed 26 Dec 2024 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $15K16,560 at $0.89 | filing |
| 23 Dec 2024filed 26 Dec 2024 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $30K33,402 at $0.90 | filing |
| 13 Dec 2024filed 17 Dec 2024 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —331,875 at $0.00 | filing |
| 13 Dec 2024filed 17 Dec 2024 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —325,000 at $0.00 | filing |
| 13 Dec 2024filed 17 Dec 2024 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —165,938 at $0.00 | filing |
| 19 Nov 2024filed 20 Nov 2024 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $6,4716,407 at $1.01 | filing |
| 19 Aug 2024filed 20 Aug 2024 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,2335,651 at $1.28 | filing |
| 17 May 2024filed 20 May 2024 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $11K6,260 at $1.75 | filing |
| 20 Feb 2024filed 22 Feb 2024 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $5,1727,606 at $0.68 | filing |
| 13 Dec 2023filed 15 Dec 2023 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —325,000 at $0.00 | filing |
| 17 Nov 2023filed 20 Nov 2023 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,5187,179 at $0.49 | filing |
News
Nektar Therapeutics (NASDAQ:NKTR) Research Coverage Started at Leerink PartnersNKTR · tickerreport.com · 15 Oct 2026Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Analysts at Leerink PartnersNKTR · themarketsdaily.com · 13 Oct 2026Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year OverhangNKTR · insidermonkey.com · 7 Oct 2026
0 headlines in the last 90 days name Mark Andrew Wilson; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.